Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Creatine monohydrate

Generic name
Creatine monohydrate
Brand name
ATC Code
C01EB06

Pharmacokinetics in children

No information

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Neuropathy, ataxia and retinitis pigmentosa (NARP), mitochondrial encephalopathy (MELAS), chronic progressive external opthalmoplegia (CPEO).
  • Oral
    • 1 month up to 18 years
      • 0.1 - 0.3 mg/kg/day in 2 doses.

      • Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.

         

    • Term neonate
      • 0.1 - 0.3 mg/kg/day in 2 doses.

      • Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.

         

    • 1 month up to 18 years
      [1]
      • 0.1 - 0.3 mg/kg/day in 2 doses.

      • Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.

         

    • Term neonate
      [1]
      • 0.1 - 0.3 mg/kg/day in 2 doses.

      • Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.

         
Kearns-Sayre syndrome (KSS)
  • Oral
    • 1 month up to 18 years
      [1]
      • 4 - 10 g/day in 2 doses.

      • Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.

    • Term neonate
      [1]
      • 4 - 10 g/day in 2 doses.

      • Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.
Arginine:glycine amidinotransferase (AGAT) deficiency
  • Oral
    • 1 month up to 18 years
      [1]
      • 300 - 400 mg/kg/day in 3 - 6 doses.

      • Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.

    • Term neonate
      [1]
      • 300 - 400 mg/kg/day in 3 - 6 doses.

      • Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.
Gyrate atrophy
  • Oral
    • ≥ 18 years
      • 1.5 - 2 g/day in 2 - 3 doses.

      • Experimental treatment (Heinanen et al. 1999)

        Treatment by or after consultations with a paediatric specialist (metabolic disorders) who has experience of using creatine monohydrate for this indication.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Prostaglandins
C01EA01
Other cardiac preparations
C01EB10
C01EB16

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Blau, Hoffmann, Leonard and Clarke, Physicians guide to the treatment and follow-up of metabolic diseases., Springer, 2006
  2. Heinänen K, et al, Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia, Eur J Clin Invest, 1999, Dec;29(12), 1060-5

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes